Wink Biotherapeutics

Targeted RNA therapeutics for a functional cure in insulin-requiring diabetes. WT817 is a modified RNA aptamer designed to selectively target pancreatic beta cells and restore beta-cell mass. Raising a $5M seed for IND-enabling studies, which unlocks a matching non-dilutive commitment from Breakthrough T1D.